Mentioned 21× · first seen 28-apr-2026 · last seen 11-oct-2026

Momelotinib

Current understanding

JAK1/2 + ACVR1 inhibitor approved for myelofibrosis with anemia. Distinguishing feature is anemia improvement via hepcidin suppression.

Evidence log

2026-10-04 — Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.: Case report: momelotinib induced hemoglobin improvement and symptom control in a patient with PCM1::JAK2 fusion-driven myeloid neoplasm, extending its anemia/symptom benefit to this rare genotype. (novelty: 3)
2026-09-01 — Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.: MAIC (observational) in ruxolitinib-pretreated MF placed momelotinib below gecacitinib on spleen-volume and symptom response endpoints, with higher GI adverse-event and discontinuation rates in the indirect comparison. (novelty: 3)
2026-08-14 — Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.: Pooled phase-3 + real-world meta-analysis characterizes momelotinib’s post-ruxolitinib profile as favoring anemia/transfusion-dependent phenotypes via its ACVR1/hepcidin effect, with spleen/symptom responses complemented by a distinct anemia-benefit signature versus fedratinib and pacritinib. (novelty: 3)
2026-04-14 — A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms: Trial-early (Phase 1/2): momelotinib being evaluated as combination backbone with JNJ-88549968 (CALR-mutation-directed agent) in CALR-mutated ET and MF — first combination of momelotinib with a mutation-specific targeted agent, extending its combination portfolio beyond ruxolitinib’s. (novelty: 4)
2026-03-31 — Momelotinib During and After HCT in Myelofibrosis: Trial-early: phase I study evaluating safety and tolerability of momelotinib administered during and after allogeneic HCT in myelofibrosis — first prospective peri-transplant evaluation of momelotinib, extending its anemia/hepcidin biology into the transplant setting. (novelty: 3)
2026-02-20 — Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis: Phase 2 trial (trial-early) evaluating combination of momelotinib with bomedemstat (LSD1 inhibitor) for MF patients with suboptimal momelotinib response or baseline cytopenias, exploring a novel mechanistic add-on strategy beyond JAK inhibition alone. (novelty: 4)
2026-04-09 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts: Trial-early: head-to-head randomized comparison of momelotinib vs ruxolitinib as first-line therapy in untreated myelofibrosis patients with cytopenias, with spleen volume reduction as the primary endpoint — first direct frontline comparison of the two JAK inhibitors in the cytopenic MF subpopulation where momelotinib’s anemia/hepcidin advantage is most relevant. (novelty: 3)
2026-04-20 — Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis: Phase 2 trial (early-stage) is evaluating momelotinib combined with luspatercept in transfusion-dependent myelofibrosis (JAKi-naïve or experienced), testing whether adding an erythroid maturation agent augments momelotinib’s anemia benefit. (novelty: 3)